TMCx company raises $16 million, Exxon scales work with Houston drone startup, and more innovation news

Short stories

The Texas Medical Center has contributed to a $16 million round in a TMCx08 member company. Courtesy of TMCx

With a busy September just days away, the Houston innovation world has seen an uptick in news. Just in case you missed some, here are some short stories from Houston startups — funding, product launches, clinical trials, oh my.

TMC invests in Luma Health's recent $16 million round

Luma Health, a San Francisco-based startup and TMCx08 cohort member, has closed a $16 million Series B round. The Texas Medical Center contributed to the round, along with U.S. Venture Partners and Cisco. PeakSpan Capital lead the series.

The company has a text-first communication platform to ease and automate the provider-patient conversations. The money, per VentureBeat, will go toward scaling up business.

"As we've spent more time with patients, doctors, and healthcare teams across the country, we've seen the disconnect between patients and clinics — patients really struggle to connect with their clinic, and clinics struggle to simply get a hold of their patients," the companies founders write on their website. "The one consistent theme we've heard after now deploying Luma Health at over 300 clinics is: how can we make it easier for our patients to get started on their care journey and connect with us as they map their personal path to healing?"

ExxonMobil scales its arrangement with Houston drone company

Dyan Gibbons

Dyan Gibbons is the CEO of Trumbull Unmanned. Courtesy of Alice

Houston-based Trumbull Unmanned has provided its drone technology to ExxonMobil since 2014. Now, the major energy company is scaling up its involvement with the local company.

Trumbull was recently awarded a five-year Unmanned Aircraft Systems Agreement and now will expand drone data collection and inspections as part of a new contract.

"Trumbull is grateful to serve amazing clients. After conducting data collection and inspections for ExxonMobil in over 25 locations, we are excited to scale operations starting in the Americas," says Trumbull CEO Dyan Gibbens in a release. "We look forward to helping ExxonMobil integrate amazing safety, efficiency, and data-driven technology into their operations."

Houston-founded startup relocates to Austin

Ben Johnson's business idea turned into a growing company making the lives of apartment dwellers easier. Courtesy of Apartment Butler

A company founded in Houston has moved its headquarters to Austin, according to reports. Spruce — formerly known as Apartment Butler — provides luxury services (like dry cleaning, cleaning, and pet services) to apartment complexes.

Founder Ben Johnson told InnovationMap last December that, even though he's raised two rounds of funding from Houston — a $2 million Seed and a $3 million Series A — it was tough to convince venture capital firms from Houston. Houston-based Mercury Fund and Austin-based Capital Factory contributed to both the company's rounds. Princeton, New Jersey-based Fitz Gate Ventures led the Series A round, and the Houston Angel Network contributed too.

"Every single VC I pitched to wanted to require us to move to Austin as a condition to our funding," Johnson tells InnovationMap in a previous article. "I wanted to grow this business in Houston. I thought I was going to have to move to Austin because there wasn't a VC for us here."

Spruce already has a presence in Austin. The company has its services in 35 Austin-area apartment complexes, per the Austin Business Journal, as well as having Austin-based employees. Earlier this year, Spruce expanded its services to Denver, representing the first out-of-state business for the company.

Houston anti-fungal fabric fashion line launches

Accel Lifestyle is a anti-stink, ethically sourced athletic line. Courtesy of Accel

Houston entrepreneur, Megan Eddings, was disappointed with the athleticwear industry. She couldn't find a company that prioritized ethical and sustainable designs that were made with a fabric that wouldn't hold on to that strong, unpleasant sweat smell. So, a chemist by trade, she made her own.

Now, after months and months of work, Eddings has launched her company and the fitness line, Accel Lifestyle. The products are made in the United States in ethical conditions and shipped in 100 percent biodegradable packaging without any plastics involved. The custom-designed fabric — called the Prema™ fabric, which is now patent pending in 120 countries — doesn't hold onto the stink from working out, meaning consumers will be less inclined to throw them away, preventing unnecessary textile waste.

"I founded Accel Lifestyle because, even though there are so many fitness apparel companies today, none of them hit all the boxes on my checklist. I wanted to support a fashionable fitness apparel company that has an ethical supply chain (no sweatshops), and a fabric that doesn't smell. What did I find? Absolutely nothing. And, I wanted to change that," says Eddings in a release. "With my science background and experience working in science labs at University of Virginia and Brown University, it took 2.5 years to create the fabric from scratch, using the most luxurious threads available and a trade secret protected science."

Houston medical device startup releases positive clinical trial results

Photo via nanospectra.com

A Houston medical device company using nanomedicine has released early results in its clinical trials treating prostrate cancer. Nanospectra Biosciences Inc.'s AuroLase technology uses laser-excited gold-silica nanoparticles with various medical imaging tools to focally remove low to intermediate grade tumors within the prostate, according to its study outcomes published in Proceedings of the National Academy of Sciences.

"As the first ultra-focal therapy for prostate cancer, AuroLase has the potential to maximize treatment efficacy while minimizing side effects associated with surgery, radiation, and traditional focal therapies," says David Jorden, CEO of Nanospectra, in a news release. "We are encouraged by the clinical success of our feasibility study to date and look forward to the initiation, potentially next month, of the pivotal study with an expected cumulative treatment population of 100 subjects."

One of the company's co-founders, Naomi J. Halas, is a professor of biophysics at Rice University.

Canadian oil and gas company with a growing presence in Houston named finalist in World Oil awards

Validere, a Canada-based energy logistics company, is expanding in Houston. Courtesy of Validere

While Houston can't completely claim Canadian oil and gas data company Validere, the company, which has a growing presence in the Bayou City, has been named a finalist in a prestigious awards program.

Validere is a finalist in the World Oil Awards' best data management and application solution award. The company is up against technology from the likes of Schlumberger, Halliburton, Siemens, NOV, Baker Hughes, and more,

The company has created a software that allows for real-time data and both artificial and human intelligence insights to improve its clients' quality, trading, and logistics. The company's technology enhances the ability of oil and gas traders to make informed decisions, which currently are made based off unreliable product quality data. Annually, $2 trillion of product moves around the oil and gas industry, and Validere uses the Internet of Things to improve the current standard of decision making.

Of course, the energy capital of the world has been a major city for growth — something co-founder Nouman Ahmad tells InnovationMap in a previous interview.

"As we think about the long-term future of the business, Houston is one of the most important markets for us going forward," Ahmad says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings